Comparison of Doses of Dexmedetomidine With Bupivacaine in Caudal Block for Duration of Analgesia in Paediatric Infraumblical Surgeries.

NCT ID: NCT04700228

Last Updated: 2021-01-07

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

162 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-02-28

Study Completion Date

2021-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Various methods are used to control post-operative pain among children. Amongst these methods, caudal block is one of the most favoured, prominent and dependable methods for providing reliable analgesia in surgeries below umbilicus.

This study is to compare two doses of Dexmedetomidine added as adjunct to local anaesthesia using reduced dose in caudal block for prolonging the duration of analgesia. Our secondary outcomes will include blood pressure, heart rate, urinary retention, nausea and vomiting in the paediatric population.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Pain is one the most underrated, misunderstood and often underdiagnosed field especially in children. Pain is an unpleasant feeling which is basically a subjective feeling, which in children is poorly expressed. Failure to control pain during childhood ultimately results in having chronic adverse effects which include altered sleep, eating habits and neuroendocrine responses and increased sensitivity to pain in the following pain episodes.

Successful postoperative pain management is one of the main pillars of anaesthesia. Regional Anaesthesia has gained a lot of popularity over the past few years in paediatrics. Approximately one-quarter of analgesic procedures currently performed on children are done by regional analgesic techniques. There are various methods that are being currently used to control post-operative pain among children. Amongst these methods, caudal block is one of the most favoured, prominent and dependable methods for providing reliable analgesia in surgeries below umbilicus. However, it has a drawback of being having a limited time of action when used as a single shot technique. This time limit can be increased significantly by the addition of different adjuvants along with local anaesthetic drugs in caudal block, which not only helps the anaesthesiologist in giving a better quality of anaesthesia and analgesia but it leads up to creating a desirable intraoperative environment for the surgeon as well. Better control over intraoperative and post-operative analgesia also helps the anaesthesiologist in giving reduced levels of anaesthesia which caused reduced amount of postoperative sedation as well.

Dexmedetomidine has a specific affinity for α2-adrenoreceptor having sedative and analgesic properties, which makes it an ideal adjuvant agent. The landmark ability of this adjuvant is that it causes minimal respiratory depression even at high dosages. A number of studies have been done until now that have proved successfully that dexmedetomidine can be used as an adjuvant in caudal block, in children, in enhancing post-operative analgesia. Although there is insufficient data available, various studies have demonstrated the dose of dexmedetomidine in Caudal Block ranging from 0.5 µg/kg to 2 µg/kg. According to an up to date review anaesthesia will last longer with dexmedetomidine as compared to morphine when used, as haemodynamics were found to be stable mostly when dexmedetomidine was used. However bradycardia was mostly related to a dose of 2 mcg/kg of dexmedetomidine. A study published in 2019 documented a decrease in heart rate, not requiring active management, in the dexmedetomidine group at a dose of 1mcg/kg.

Our objective is to compare two doses of Dexmedetomidine added as adjunct to local anaesthesia using reduced dose in caudal block for prolonging the duration of analgesia. Our secondary outcomes will include blood pressure, heart rate, urinary retention, nausea and vomiting in the paediatric population.

Patient meeting inclusion criteria visiting paediatric operating room will be inducted in the study. Informed and written consent will be taken from parents/guardian explained about the potential risk and benefits of study. Patients' demographic details like age, sex, and weight will be collected by filling the relevant proforma. A total of 162 patients will be divided into three equal groups randomly by lottery method. The observer and the anaesthesiologist who will induce the patient will be blinded regarding the group in which the patient will be placed.

Pre operatively, a detailed history, examination and related laboratory investigations will be seen as a part of hospital pre-operative assessment protocol. On arrival to operation theatre, monitors (SpO2, Pulse Oximeter, NIBP, pre cordial stethoscope and ECG) will be applied. Emergency drugs will be prepared already before the patient arrives in operation theatre. Anaesthesia will be induced with 100% oxygen and sevoflurane 8% using Jackson Rees Circuit. Once the desired depth of anaesthesia is achieved, I/V access will be taken. Propofol 3mg/kg and Nalbuphine 0.1mg/kg will be given and Sevoflurane will be set at 3%. LMA of desirable size will be placed. After this, patient would be placed in lateral position. Sufficient exposure would be done for Caudal Block. After taking all aseptic measures, Caudal Block procedure will be done with help of 23G needle after identifying the anatomical landmarks. Correction position of the needle will be confirmed by swoosh and whoosh test. On aspiration of the syringe if it is negative for CSF and blood, then one of the following drug combinations will be used for the caudal block.

Group C (control): 0.25% bupivacaine at a total volume of 0.5ml/kg Group BD1: 0.25% bupivacaine + 1mcg/kg dexmedetomidine at a total volume of 0.5ml/kg Group BD2: 0.25% bupivacaine + 0.5mcg/kg dexmedetomidine at a total volume of 0.5ml/kg After dressing the injection site, the patient will be turned supine. Vitals of the patient including heart rate, blood pressure, SpO2 and respiratory will be recorded before the induction of caudal block and there after every 10 minutes. Inadequate analgesia or unsuccessful block will be labelled if there would be a 20% increase in heart rate of the patient as compared to the baseline recording. If the caudal block is insufficient that case will not be included in the study. Hypotension and bradycardia will be recorded and treated with fluid bolus and atropine respectively. . The first surgical incision would be given 10 mins after the application of caudal block. After the completion of the surgery, inhalation gas will be closed and patient will be given 100% oxygen only. LMA will be removed once the patient is awake and the patient will be shifted to Post Anaesthesia Care Unit (PACU). Here patient's vitals will be monitored and pain will be assessed at 1, 2, 4, 6 and 12 hours after the application of caudal block using FLACC scale16. Time taken for the requirement of first rescue analgesia will also be recorded. Intravenous paracetamol 15mg/kg will be given if FLACC score is more than 4 at any of the above mentioned time. Secondary findings like heart rate, blood pressure, respiratory depression, urinary retention, nausea and vomiting will also be recorded.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pain, Postoperative

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

FACTORIAL

Factorial Assignment Anesthesia will be induced with 100% oxygen and sevoflurane 8%. Once achieving the desired depth of anesthesia, I/V access will be taken. Propofol 3mg/kg and Nalbuphine 0.1mg/kg will be given. LMA of desirable size will be placed. After this, patient would be placed in lateral position for caudal Block. After all aseptic measures, Caudal Block procedure will be done with help of 23G needle by anatomical landmarks. On negative aspiration of the syringe, one of the drug combinations as explained under 'arms and intervention' will be used for the caudal block. First surgical incision will be given 10 mins after the application of caudal block. After the completion of surgery, LMA will be removed once the patient is awake and the patient will be shifted to PACU. IV paracetamol 15mg/kg will be given if FLACC score is more than 4 at any point during the surgery.
Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Caregivers

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group C

0.25% bupivacaine at a total volume of 0.5ml/kg.

Group Type PLACEBO_COMPARATOR

Bupivacaine Hydrochloride

Intervention Type DRUG

We are going to see the effects of dexmedetomidine as an adjunct to bupivacaine in caudal block. In first (control) group (group C) only bupivacaine will be given. Group BD1 patients will be given bupivacaine plus 1mcg/kg dexmedetomidine. Group BD2 patients will get bupivacaine plus 0.5mcg/kg dexmedetomidine. All the groups will be given a volume of 0.5ml/kg.

Group BD1

0.25% bupivacaine + 1mcg/kg dexmedetomidine at a total volume of 0.5ml/kg.

Group Type ACTIVE_COMPARATOR

Bupivacaine Hydrochloride

Intervention Type DRUG

We are going to see the effects of dexmedetomidine as an adjunct to bupivacaine in caudal block. In first (control) group (group C) only bupivacaine will be given. Group BD1 patients will be given bupivacaine plus 1mcg/kg dexmedetomidine. Group BD2 patients will get bupivacaine plus 0.5mcg/kg dexmedetomidine. All the groups will be given a volume of 0.5ml/kg.

Dexmedetomidine

Intervention Type DRUG

We are going to see the effects of dexmedetomidine as an adjunct to bupivacaine in caudal block. In first (control) group (group C) only bupivacaine will be given. Group BD1 patients will be given bupivacaine plus 1mcg/kg dexmedetomidine. Group BD2 patients will get bupivacaine plus 0.5mcg/kg dexmedetomidine. All the groups will be given a volume of 0.5ml/kg.

Group BD2

0.25% bupivacaine + 0.5mcg/kg dexmedetomidine at a total volume of 0.5ml/kg.

Group Type ACTIVE_COMPARATOR

Bupivacaine Hydrochloride

Intervention Type DRUG

We are going to see the effects of dexmedetomidine as an adjunct to bupivacaine in caudal block. In first (control) group (group C) only bupivacaine will be given. Group BD1 patients will be given bupivacaine plus 1mcg/kg dexmedetomidine. Group BD2 patients will get bupivacaine plus 0.5mcg/kg dexmedetomidine. All the groups will be given a volume of 0.5ml/kg.

Dexmedetomidine

Intervention Type DRUG

We are going to see the effects of dexmedetomidine as an adjunct to bupivacaine in caudal block. In first (control) group (group C) only bupivacaine will be given. Group BD1 patients will be given bupivacaine plus 1mcg/kg dexmedetomidine. Group BD2 patients will get bupivacaine plus 0.5mcg/kg dexmedetomidine. All the groups will be given a volume of 0.5ml/kg.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Bupivacaine Hydrochloride

We are going to see the effects of dexmedetomidine as an adjunct to bupivacaine in caudal block. In first (control) group (group C) only bupivacaine will be given. Group BD1 patients will be given bupivacaine plus 1mcg/kg dexmedetomidine. Group BD2 patients will get bupivacaine plus 0.5mcg/kg dexmedetomidine. All the groups will be given a volume of 0.5ml/kg.

Intervention Type DRUG

Dexmedetomidine

We are going to see the effects of dexmedetomidine as an adjunct to bupivacaine in caudal block. In first (control) group (group C) only bupivacaine will be given. Group BD1 patients will be given bupivacaine plus 1mcg/kg dexmedetomidine. Group BD2 patients will get bupivacaine plus 0.5mcg/kg dexmedetomidine. All the groups will be given a volume of 0.5ml/kg.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* American Society of Anaesthesiologists (ASA) Status I and II
* Aged between 1 to 6 years
* Planned for below umbilicus elective surgery

Exclusion Criteria

* Refusal to consent by parent/guardian
* Injection site infection
* Coagulation disorders
* Congenital abnormalities of lower spine and meninges
* Anticipated difficult airway requiring endotracheal intubation and intermittent positive pressure ventilation
* Prone position surgical procedures
* Known drug allergy history
Minimum Eligible Age

1 Year

Maximum Eligible Age

6 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Dr. Ruth K.M. Pfau Civil Hospital, Karachi

OTHER_GOV

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Haris Chohan

Faculty Member

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Haris Chohan, FCPS Pakistan

Role: PRINCIPAL_INVESTIGATOR

Dr. Ruth KM Pfau Civil Hospital, Dow University of Health Sciences Karachi, Pakistan

Syed Farjad Sultan, FCARCSI, PhD

Role: PRINCIPAL_INVESTIGATOR

Dr. Ruth KM Pfau Civil Hospital, Dow University of Health Sciences Karachi, Pakistan

Arun Kumar, FCPS

Role: PRINCIPAL_INVESTIGATOR

Dr. Ruth KM Pfau Civil Hospital, Dow University of Health Sciences, Karachi, Pakistan

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Dr. Haris Chohan

Karachi, Sindh, Pakistan

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Pakistan

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Haris123

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Role of Dexmedetomidine as Synergistic Agent
NCT06662175 NOT_YET_RECRUITING PHASE2/PHASE3
Post- Thoracotomy Paravertebral Block
NCT02886429 COMPLETED PHASE2